Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

A recent Diagnostics study discusses the specific antibody response that occurred in individuals after they had received the SARS-CoV-2 vaccine.

1 Jul 2021

Can age, sex, BMI or blood group influence the immunogenicity of the Pfizer/BioNTech COVID-19 vaccine?

A group of Belgium researchers recently discuss their findings in the journal Microorganisms, which describe the influence of several factors on vaccine-induced immunogenicity.

1 Jul 2021

FairJourney Biologics introduces “THE ANTIBODY SERIES” conference

FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, today announced the launch of the “THE ANTIBODY SERIES” - a 1-day conference bringing together top experts in the antibody field to explore the latest innovation within antibody drug discovery.

From FairJourney Biologics S.A. 1 Jul 2021

People with COVID-19 frequently infect their pets and cats are particularly at risk

Previous studies have shown that cats and dogs can catch COVID-19 from their owners, but new research is attempting to understand how and why this occurs.

1 Jul 2021

COVID-19 vaccines are effective in 94% of cancer patients, shows study

In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.

1 Jul 2021

Research shows COVID-19-mRNA vaccine efficiency against coronavirus variants

A new Finnish study shows that 180 health care workers who had received two doses of the Pfizer and Biontech vaccine have very good antibody responses against the SARS-CoV-2 virus. The immune response was as strong against the alpha variant (formerly the UK variant) but was somewhat decreased against the beta variant (formerly the South Africa variant).

1 Jul 2021

COVID mRNA vaccines induce antibodies against three SARS-CoV-2 variants

Researchers at the Institute of Biomedicine, the University of Turku in Finland showed that the blood of BNT162b2-vaccinated health care workers effectively neutralized the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant (Alpha variant) after the second dose.

1 Jul 2021

Study highlights changes within SARS-CoV-2 variants that could be exploited to design effective inhibitors

A computational study that analyzes and explores the time-based structures of the SARS-CoV-2 variants with specific spike (S) protein mutations is discussed here.

30 Jun 2021

Alpha variant mutations help SARS-CoV-2 overcome evolutionary weaknesses

The study, published in the journal Cell Reports, showed that the mutations in the virus, particularly the deletion of two amino acids H69/V70 seen in the Alpha variant (B.1.1.7), enables the virus to overcome weaknesses as it evolves.

30 Jun 2021

Antibody development against SARS-CoV-2 following Moderna vaccine

In a paper recently uploaded to the preprint server medRxiv* by Belda et al. (June 27th, 2021) two seroconversion panels containing the sera of individuals that received the Moderna (mRNA-1273) vaccine are compared, and the impact on neutralizing IgG antibody titers in these individuals is analyzed.

30 Jun 2021

Moderna's COVID vaccine effective against emerging variants including Delta

Researchers in the United States have analyzed the neutralizing activity of Moderna’s mRNA-1273 vaccine against several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

A team of US-based scientists recently developed a novel vaccine candidate against SARS-CoV-2, the causative pathogen of COVID-19. The vaccine is composed of extracellular vesicles of Salmonella typhimurium incorporated with the spike receptor-binding domain (RBD) of SARS-CoV-2. Upon intranasal administration in hamsters, the vaccine induces strong blood antibody titers and protects against severe COVID-19.

30 Jun 2021

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

A new study in the UK, by researchers at Imperial College London, The Francis Crick Institute and the University of Glasgow, explores the loss of coronavirus disease 2019 (COVID-19) vaccine efficacy against the virus behind the current pandemic caused by the emergence of newer variants that have undergone mutational escape.

30 Jun 2021

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

New clinical trial data, recently published in The Lancet’s Infectious Diseases, presents an initial report on the effect of an inactivated SARS-CoV-2 vaccine, CoronaVac, on children and adolescents from ages 3-17 in a double-blind, randomized setting.

30 Jun 2021

Widespread SARS-CoV-2 mutation escapes vaccine- and infection-induced CD8 T-cell responses

Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.

29 Jun 2021

Six antibody features could be used to identify women at risk of placental malaria

Six antibody characteristics could help scientists identify which pregnant women are at risk of placental malaria infections, finds a study published today in eLife.

29 Jun 2021

More evidence that mixing COVID-19 vaccines may help elicit a robust immune response

Eight volunteers who received a complete dose or a single dose of an mRNA vaccine or the ChAdOx1 vaccine after a dose of a trial gorilla adenovirus vaccine showed a significantly high level of antibodies and T cell response against SARS-CoV-2.

29 Jun 2021

Nanotechnology and the fight against COVID-19

In a review paper published in the open-access MDPI journal Viruses, a team of researchers explored the potential of nanotechnology to alleviate the current and future coronavirus burden. The team focused on its potential role in the detection, diagnosis, protection, and treatment of SARS-CoV-2 infection.

29 Jun 2021

New spider web mechanism kills pathogens and virus responsible for COVID-19

Immunologists at McMaster University have discovered a previously unknown mechanism which acts like a spider web, trapping and killing pathogens such as influenza or SARS-CoV-2, the virus responsible for COVID-19.

29 Jun 2021

Tackling emerging SARS-CoV-2 variants

An international team of authors has published a special report in The New England Journal of Medicine titled 'SARS-CoV-2 Variants and Vaccines’, which presents global strategies for the possible escape from vaccine-elicited immunity.

29 Jun 2021

Antibody News and Research

Further Reading

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

Can age, sex, BMI or blood group influence the immunogenicity of the Pfizer/BioNTech COVID-19 vaccine?

FairJourney Biologics introduces “THE ANTIBODY SERIES” conference

People with COVID-19 frequently infect their pets and cats are particularly at risk

COVID-19 vaccines are effective in 94% of cancer patients, shows study

Research shows COVID-19-mRNA vaccine efficiency against coronavirus variants

COVID mRNA vaccines induce antibodies against three SARS-CoV-2 variants

Study highlights changes within SARS-CoV-2 variants that could be exploited to design effective inhibitors

Alpha variant mutations help SARS-CoV-2 overcome evolutionary weaknesses

Antibody development against SARS-CoV-2 following Moderna vaccine

Moderna's COVID vaccine effective against emerging variants including Delta

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

Widespread SARS-CoV-2 mutation escapes vaccine- and infection-induced CD8 T-cell responses

Six antibody features could be used to identify women at risk of placental malaria

More evidence that mixing COVID-19 vaccines may help elicit a robust immune response

Nanotechnology and the fight against COVID-19

New spider web mechanism kills pathogens and virus responsible for COVID-19

Tackling emerging SARS-CoV-2 variants

Event guide: Targeted Therapies Partnering & Licensing Summit Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo